Exchange: NASDAQ·Updated 05:23 PM EDT
NXTC logo

NXTCNextcure Inc

$2.12
$0.18
(8.18%)
Today
Closed $2.02
$0.10
(4.95%)
After Hours
Reported EarningsMay 7
Mkt Cap$7.95M
Vol59,376.00
News
all
press releases
What's Going On With NextCure Stock Wednesday?
NextCure ($NXTC) rises 2.1% premarket after presenting positive Phase 1 clinical data for ovarian cancer treatment SIM0505 at ASCO.read more...
Benzinga
News Placeholder
More News
News Placeholder
NextCure Shares Jump 15% After Private Placement Announcement
(RTTNews) - NextCure, Inc. (NXTC) rose 14.88% to $9.61, up $1.24, after announcing it has entered into a private placement of approximately $21.5 million, issuing 2,523,477 shares of common stock or...
Nasdaq News: Markets
News Placeholder
Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
News Placeholder
NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment
NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility.
Stocktwits
News Placeholder
NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline
The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors.
Stocktwits
News Placeholder
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe
Stocktwits Contributor
<
...
1
>

Advertisement|Remove ads.